石药集团(01093.HK)：SYS 6010联合恩朗苏拜单抗用于治疗未经系统性治疗的驱动基因阴性晚期NSCLC的I / II期临床研究数据于2026年世界肺癌大会(WCLC)上以口头报告形式公布

智通财经09-14 17:34

【石药集团(01093.HK)：SYS 6010联合恩朗苏拜单抗用于治疗未经系统性治疗的驱动基因阴性晚期NSCLC的I / II期临床研究数据于2026年世界肺癌大会(WCLC)上以口头报告形式公布】智通财经APP讯，石药集团(01093.HK)公布，集团已于国际肺癌研究协会(IASLC)主办的2026年世界肺癌大会(WCLC)上，以口头报告形式公布SYS6010联合恩朗苏拜单抗用于治疗未经系统性治疗的驱动基因阴性晚期非小细胞肺癌(NSCLC)的I/II期临床研究数据。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2667269654?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-14 17:34","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2667269654","market":"us","top_or_hot":-1,"title":"石药集团(01093.HK)：SYS 6010联合恩朗苏拜单抗用于治疗未经系统性治疗的驱动基因阴性晚期NSCLC的I / II期临床研究数据于2026年世界肺癌大会(WCLC)上以口头报告形式公布","media":"智通财经","content":"<html><body><div>\n<div>\n<b>【石药集团(01093.HK)：SYS 6010联合恩朗苏拜单抗用于治疗未经系统性治疗的驱动基因阴性晚期NSCLC的I / II期临床研究数据于2026年世界肺癌大会(WCLC)上以口头报告形式公布】</b>智通财经APP讯，石药集团(01093.HK)公布，集团已于国际肺癌研究协会(IASLC)主办的2026年世界肺癌大会(WCLC)上，以口头报告形式公布SYS6010联合恩朗苏拜单抗用于治疗未经系统性治疗的驱动基因阴性晚期非小细胞肺癌(NSCLC)的I/II期临床研究数据。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药集团(01093.HK)：SYS 6010联合恩朗苏拜单抗用于治疗未经系统性治疗的驱动基因阴性晚期NSCLC的I / II期临床研究数据于2026年世界肺癌大会(WCLC)上以口头报告形式公布</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药集团(01093.HK)：SYS 6010联合恩朗苏拜单抗用于治疗未经系统性治疗的驱动基因阴性晚期NSCLC的I / II期临床研究数据于2026年世界肺癌大会(WCLC)上以口头报告形式公布\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【石药集团(01093.HK)：SYS 6010联合恩朗苏拜单抗用于治疗未经系统性治疗的驱动基因阴性晚期NSCLC的I / II期临床研究数据于2026年世界肺癌大会(WCLC)上以口头报告形式公布】</b>智通财经APP讯，石药集团(01093.HK)公布，集团已于国际肺癌研究协会(IASLC)主办的2026年世界肺癌大会(WCLC)上，以口头报告形式公布SYS6010联合恩朗苏拜单抗用于治疗未经系统性治疗的驱动基因阴性晚期非小细胞肺癌(NSCLC)的I/II期临床研究数据。                </div>\n</div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2667269654","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667269654","pubTimestamp":1789378468,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【石药集团(01093.HK)：SYS 6010联合恩朗苏拜单抗用于治疗未经系统性治疗的驱动基因阴性晚期NSCLC的I / II期临床研究数据于2026年世界肺癌大会(WCLC)上以口头报告形式公布】","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01093":"石药集团","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","BK1191":"制药","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","KURE":"KraneShares MSCI All China Health Care Index ETF","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","BK1515":"抗疫概念","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1521":"挪威政府全球养老基金持仓","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","IE0008368742.USD":"首域中国增长基金I Acc","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC"},"translate_title":"CSPC Pharmaceutical Group (01093.HK): Data from the Phase I/II clinical trial of SYS 6010 combined with Enlangsubimab for the treatment of driver gene-negative advanced NSCLC without systemic treatment will be presented orally at the 2026 World Congress on Lung Cancer (WCLC).","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1.5,"KURE":0.6},"content_text":"【石药集团(01093.HK)：SYS 6010联合恩朗苏拜单抗用于治疗未经系统性治疗的驱动基因阴性晚期NSCLC的I / II期临床研究数据于2026年世界肺癌大会(WCLC)上以口头报告形式公布】智通财经APP讯，石药集团(01093.HK)公布，集团已于国际肺癌研究协会(IASLC)主办的2026年世界肺癌大会(WCLC)上，以口头报告形式公布SYS6010联合恩朗苏拜单抗用于治疗未经系统性治疗的驱动基因阴性晚期非小细胞肺癌(NSCLC)的I/II期临床研究数据。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2667269654","isCrawlerRequest":true}